Inside information pursuant to Article 17 MAR
Heidelberg Pharma AG Announces Adjustment of Guidance
Heidelberg Pharma AG today announced that it has adjusted its guidance for the current fiscal year published in March This is due to lower development expenses because clinical testing and manufacturing orders were delayed. Planned sales revenue from license agreements will not be recognized until the next fiscal year as some of the partners will reach milestones later than projected. Overall, the operating result will improve and funding requirements for fiscal year 2021 will decrease.